Stimulant Oxytocin Study

Completed · Phase 2 · Has a placebo group

Conditions studied: Stimulant Use & Co-occuring Opioid Use Disorders

In brief

This study will investigate the effects of intranasal administration of oxytocin, a social neuropeptide, on reducing stimulant use, enhancing therapeutic engagement, and susceptibility to stress-induced relapse in Veterans with stimulant use disorders and enrolled in opioid replacement therapy (ORT) program for co-occurring opioid use disorder (OUD).

Key facts

Study ID: NCT03016598
Run by: VA Office of Research and Development
People needed: 42
Starts: 2018-01-26
Expected to finish: 2020-02-14
Last updated by the study team: 2021-06-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

At least 18 years old
Enrolled as a patient who at the SFVAMC Opioid Treatment Program or the Oakland Behavioral Health Clinic Opioid Treatment Program
Stable dose of opioid replacement therapy for at least 2 consecutive weeks
Veteran
One documented urine toxicology screen positive for stimulants in the past 12 months.

You may not qualify if…

Severe neuropsychological disorder
Suicidal or homicidal ideation within the past 90 days or a suicide attempt in the past 6 months
Hemodialysis, unless participant can produce urine samples weekly
Sensitivity to methylparaben or propylparaben
Positive urine pregnancy test or women of childbearing age not practicing effective means of non-hormonal birth control
Chronic nasal obstruction, discharge, or bleeding

Where it is running

VA Northern California Health Care System, Mather, CA — Sacramento, California, United States
San Francisco VA Medical Center, San Francisco, CA — San Francisco, California, United States
VA Portland Health Care System, Portland, OR — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.